Lumexa Imaging Holdings, Inc.

Lumexa Imaging Holdings, Inc. reported a net income of $2.7 million for the second quarter of 2026, a significant improvement from a net loss of $7.2 million in the same period last year. Total revenues for the quarter increased to $264.2 million. For the first six months of 2026, the company achieved a net income of $4.5 million, reversing a $14.9 million net loss in the prior year, and generated $35.7 million in positive cash flow from operations.

Lumexa Imaging Holdings, Inc. reported its second quarter 2026 financial results, achieving a net income of $2.7 million, a significant improvement from a net loss of $7.2 million in the prior year. Consolidated revenues increased by 5.1% to $264.2 million. The company also announced four new imaging centers year-to-date and a joint venture with Hospital for Special Surgery (HSS). Lumexa Imaging reiterated its full-year 2026 consolidated revenue guidance and narrowed its Adjusted EBITDA guidance range.

Lumexa Imaging Holdings, Inc. announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026. The company will host a conference call and live webcast to discuss these results at 5:00 p.m. ET. The webcast will be accessible via the Investor Relations section of its website, with a replay available for about one year.

Lumexa Imaging Holdings, Inc. announced an amendment to its Credit Agreement, establishing a new secured term loan facility of approximately $823 million and a secured revolving line of credit of $250 million. The term loan matures in December 2032 and the revolving facility in December 2030, both bearing interest at SOFR plus 2.50% or Prime Rate plus 1.50%. The agreement includes restrictive covenants and a financial covenant requiring a consolidated net leverage ratio not exceeding 7.50 to 1 under certain conditions.

Lumexa Imaging Holdings, Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026. Stockholders elected three Class I directors—Lee Cooper, Brian Regan, and Caitlin Zulla—to serve until the 2029 Annual Meeting. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified. As of the record date, 96,110,039 shares were outstanding and entitled to vote.

Lumexa Imaging announced a strategic joint venture with Hospital for Special Surgery (HSS), a world leader in musculoskeletal health. This collaboration represents Lumexa Imaging's ninth joint venture and significantly strengthens its presence in the New York City metro area. The partnership aims to expand access to advanced outpatient imaging services, bringing high-quality, convenient care closer to patients and providers. This move aligns with Lumexa Imaging's long-term growth strategy focused on expanding in attractive markets and meeting growing demand.

Lumexa Imaging Holdings, Inc. reported a significant financial turnaround for Q1 2026, swinging to a net income of $1.7 million, or $0.02 per diluted share, compared to a net loss of $7.7 million in Q1 2025. Total revenues increased by 3.1% to $252.5 million. The company also saw a substantial improvement in cash flow from operations, turning positive at $2.9 million, and a 45.3% reduction in interest expense, largely due to debt paydown from its December 2025 IPO.

Lumexa Imaging reported its first quarter 2026 results, with consolidated revenues increasing 3.1% to $252.5 million and net income reaching $1.7 million, a significant improvement from a net loss of $7.7 million in the prior year. The company also announced the addition of four new imaging centers, including two strategic acquisitions and two de novo centers, progressing towards its goal of 8-10 de novos this year. Lumexa Imaging reiterated its full-year 2026 guidance for consolidated revenues and Adjusted EBITDA, expressing confidence in sustained profitable growth.

Lumexa Imaging Holdings, Inc. (LMRI) announced its Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 8:30 a.m. Eastern Time. Stockholders will vote on the election of three Class I directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the year ending December 31, 2026. The Board unanimously recommends voting for all proposals, and the record date for voting is April 13, 2026.

Lumexa Imaging Holdings, Inc. (LMRI) announced on April 8, 2026, that it reiterated its previously disclosed full year 2026 guidance. This reaffirmation occurred during a scheduled meeting and site visit with investors. The company's decision to maintain its existing outlook suggests stability in its operational performance and market expectations for the current fiscal year. For investors, this indicates that there are no immediate changes to the company's financial projections, reinforcing the previously communicated strategic direction and anticipated results.